
June 30 (Reuters) - Unicycive Therapeutics Inc UNCY.O:
UNICYCIVE THERAPEUTICS ANNOUNCES RECEIPT OF COMPLETE RESPONSE LETTER FOR OXYLANTHANUM CARBONATE FOR THE TREATMENT OF HYPERPHOSPHATEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS
UNICYCIVE THERAPEUTICS INC - CRL CITES DEFICIENCIES AT THIRD-PARTY MANUFACTURING VENDOR UNRELATED TO OLC
UNICYCIVE THERAPEUTICS INC - TO REQUEST TYPE A MEETING WITH FDA TO ALIGN ON NEXT STEPS
UNICYCIVE THERAPEUTICS INC - SECOND MANUFACTURING VENDOR IDENTIFIED TO RESOLVE CMC ISSUES IN CRL
UNICYCIVE THERAPEUTICS INC - NO OTHER CONCERNS STATED IN CRL, INCLUDING PRE-CLINICAL, CLINICAL, OR SAFETY DATA